← Back

News

Monday, 07 May 2018

When Prof. Kostas Kostarelos came to the ICN2

Professor and chair of nanomedicine at the University of Manchester explains why a new work package on biomedical technologies was needed within the Graphene Flagship, and why the Bellaterra Campus is so important to this new line of research.

When Prof. Kostas Kostarelos, chair of nanomedicine at the University of Manchester and the face of the Graphene Flagship biomedical technologies work package, came to the ICN2, we couldn't let him go without first giving us a short interview. In it he explains how a new line of research devoted exclusively to biomedical technologies was needed within the Graphene Flagship in response to the increasing global demand for graphene by the biomedical community, for use in new therapeutic technologies and devices. Given that the ultimate goal of the Flagship is to be of service to EU citizens, it makes a lot of sense to pay this kind of attention to a line with such clear social benefits.

Among the things that Kostas was keen to highlight, and something we are equally keen to stress here, was that graphene is not one material. Often misrepresented by the media and even the scientific community when addressing a general public, there are actually many types of graphene, each of which has a different properties that make it uniquely suited for different applications. Indeed, much work goes on to integrate different kinds of graphene into a single platform or device.

 

Prof. Kostas Kostarelos was hosted by ICREA Prof. Jose A. Garrido, leader of the ICN2 Advanced Electronic Materials and Devices Group.